News on Medtronic (Ticker: MDT) continually updated from thousands of sources around the net.
Tuesday | The Motley Fool
That's led to recent acquisitions including a $170 million deal to acquire Endosense, an atrial fibrillation, or AF, catheter company that St. Jude hopes will give it a leg up against competitors Boston Scientific and Medtronic .
Are You as Liberal as President Obama?
Do You Know the NRA?
Author's Note: This article discusses a microcap stock. Please be advised of the risks associated with microcap stocks.
In a report published Thursday, Citigroup analyst Matthew J. Dodds reiterated a Buy rating on Medtronic , and raised the price target from $62.00 to $69.00.
The firm currently has a "neutral" rating on the stock. Wedbush's price target would suggest a potential downside of 3.32% from the stock's previous close.
The firm currently has an "outperform" rating on the stock. BMO Capital Markets' price target indicates a potential upside of 12.50% from the company's current price.
Comments from the Federal Reserve's current chief Ben Bernanke cemented investor expectations that the US central bank would hold off on tapering in December.
Unless you are living on a different planet, you are well aware that there has been a large-scale flight of "The healthcare VC asset class is like the red-headed step child to the pension funds, funds of funds," and other institutional investors from whom venture capitalists raise money, said Conrad Wang, Senior Director of Corporate Development at ... (more)
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
Medtronic's Cardiac and Vascular Group, which includes operations in Santa Rosa, on Tuesday reported second-quarter sales increased 3 percent from a year before, slightly faster growth than for the company as a whole.
That's the conclusion of one stock market analyst, at least, following second-quarter financial results released Tuesday from Fridley-based Medtronic that slightly beat expectations for earnings.
For its fiscal Q2 ended Oct. 25, Medtronic made 91 cents a share, up 3.4% from the year-earlier quarter and a penny over analysts' consensus.
At this time, I would like to welcome everyone to the Medtronic second quarter earnings conference call.
Medtronic Inc on Tuesday reported higher quarterly earnings that were slightly above analysts' expectations on stronger sales of its implantable devices to treat abnormal heart rhythms.
Medtronic issued its quarterly earnings data on Tuesday. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.90 by $0.01, Analyst Ratings Network reports.